Vittoria Bocchi, Julia Brunner, Melissa Yao, Tzippora Chwat-Edelstein named 2024 Kravis WiSE fellows

Susan Ellenberg started out as a high school math teacher—then became a leading biostatistician

A mathematical puzzle fascinated Susan Ellenberg as a child.

October 25, 2024

Latino oncology leaders discuss representation in clinical trials, translational research, and health care
Mesa, Carvajal-Carmona, Cruz-Correa, Perez, Ramirez, Sanchez: “We’re here to help lead and collaborate.”

Hispanic and Latino people comprise nearly 20% of the U.S. population, but less than 6% of physicians nationwide identify as Hispanic.

October 11, 2024

Vol.50 No.38

By Ruben A. Mesa and McKenzie Prillaman

Conversation with The Cancer Letter

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Every summer since 2010, ten undergraduate students from diverse backgrounds get the opportunity to explore any curiosities they might have about careers in medicine at Memorial Sloan Kettering Cancer Center.

October 04, 2024

Vol.50 No.37

By Claire Marie Porter

In Brief

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Four NCI-designated cancer centers—Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins—have joined together and secured funding from AWS, Deloitte, Microsoft, and NVIDIA, to create the Cancer AI Alliance.

October 04, 2024

Vol.50 No.37

PubMed’s failure to display all papers by authors who publish under multiple names “mistreats women,” lawsuit contends

A law group associated with conservative causes and funded by leading conservative donors has sued NIH, HHS, and the National Library of Medicine, demanding that the institutions address PubMed’s inability to display all papers authored by researchers who have published under multiple names.

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

September 13, 2024

Vol.50 No.34

By McKenzie Prillaman

Vittoria Bocchi, Julia Brunner, Melissa Yao, Tzippora Chwat-Edelstein named 2024 Kravis WiSE fellows

YOU MAY BE INTERESTED IN

Susan Ellenberg started out as a high school math teacher—then became a leading biostatistician

Latino oncology leaders discuss representation in clinical trials, translational research, and health care
Mesa, Carvajal-Carmona, Cruz-Correa, Perez, Ramirez, Sanchez: “We’re here to help lead and collaborate.”

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

PubMed’s failure to display all papers by authors who publish under multiple names “mistreats women,” lawsuit contends

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Renew today!

Subscriber content

Login

Vittoria Bocchi, Julia Brunner, Melissa Yao, Tzippora Chwat-Edelstein named 2024 Kravis WiSE fellows

YOU MAY BE INTERESTED IN

Susan Ellenberg started out as a high school math teacher—then became a leading biostatistician

Latino oncology leaders discuss representation in clinical trials, translational research, and health careMesa, Carvajal-Carmona, Cruz-Correa, Perez, Ramirez, Sanchez: “We’re here to help lead and collaborate.”

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

PubMed’s failure to display all papers by authors who publish under multiple names “mistreats women,” lawsuit contends

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Login

Latino oncology leaders discuss representation in clinical trials, translational research, and health care
Mesa, Carvajal-Carmona, Cruz-Correa, Perez, Ramirez, Sanchez: “We’re here to help lead and collaborate.”

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies